|
1
|
Hynes NE and Lane HA: ERBB receptors and
cancer: The complexity of targeted inhibitors. Nat Rev Cancer.
5:341–344. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pao W and Chmielecki J: Rational,
biologically based treatment of EGFR-mutant non-small-cell lung
cancer. Nat Rev Cancer. 10:760–774. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cataldo VD, Gibbons DL, Pérez-Soler R and
Quintás-Cardama A: Treatment of non-small-cell lung cancer with
erlotinib or gefitinib. N Engl J Med. 364:947–955. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wheeler DL, Dunn EF and Harari PM:
Understanding resistance to EGFR inhibitors-impact on future
treatment strategies. Nat Rev Clin Oncol. 7:493–507. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kobayashi S, Boggon TJ, Dayaram T, Jänne
PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos
B: EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pao W, Miller VA, Politi KA, Riely GJ,
Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of
lung adenocarcinomas to gefitinib or erlotinib is associated with a
second mutation in the EGFR kinase domain. PLoS Med. 2:e732005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yun CH, Mengwasser KE, Toms AV, Woo MS,
Greulich H, Wong KK, Meyerson M and Eck MJ: The T790M mutation in
EGFR kinase causes drug resistance by increasing the affinity for
ATP. Proc Natl Acad Sci USA. 105:pp. 2070–2075. 2008; View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Engelman JA, Zejnullahu K, Mitsudomi T,
Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen
J, et al: MET amplification leads to gefitinib resistance in lung
cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sequist LV, Waltman BA, Dias-Santagata D,
Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S
and Heist RS: Genotypic and histological evolution of lung cancers
acquiring resistance to EGFR inhibitors. Sci Transl Med.
3:75ra262011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zakowski MF, Ladanyi M and Kris MG;
Memorial Sloan-Kettering Cancer Center Lung Cancer OncoGenome
Group, : EGFR mutations in small-cell lung cancers in patients who
have never smoked. N Engl J Med. 355:213–215. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu HA, Arcila ME, Rekhtman N, Sima CS,
Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ:
Analysis of tumor specimens at the time of acquired resistance to
EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Clin Cancer Res. 19:2240–2247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Suda K, Tomizawa K, Fujii M, Murakami H,
Osada H, Maehara Y, Yatabe Y, Sekido Y and Mitsudomi T: Epithelial
to mesenchymal transition in an epidermal growth factor
receptor-mutant lung cancer cell line with acquired resistance to
erlotinib. J Thorac Oncol. 6:1152–1161. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
van 't Veer LJ, Dai H, van de Vijver MJ,
He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ,
Witteveen AT, et al: Gene expression profiling predicts clinical
outcome of breast cancer. Nature. 415:530–536. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ruzzo A, Graziano F, Loupakis F, Rulli E,
Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P and
Bisonni R: Pharmacogenetic profiling in patients with advanced
colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J
Clin Oncol. 25:1247–1254. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ono M, Hirata A, Kometani T, Miyagawa M,
Ueda S, Kinoshita H, Fujii T and Kuwano M: Sensitivity to gefitinib
(Iressa, ZD1839) in non-small cell lung cancer cell lines
correlates with dependence on the epidermal growth factor (EGF)
receptor/extracellular signal-regulated kinase 1/2 and EGF
receptor/Akt pathway for proliferation. Mol Cancer Ther. 3:465–472.
2004.PubMed/NCBI
|
|
16
|
Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II,
Yang SH, Lee SS, Kim CH, Yoo YD and Lee JC: The role of MET
activation in determining the sensitivity to epidermal growth
factor receptor tyrosine kinase inhibitors. Mol Cancer Res.
7:1736–1743. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lange A, Thon L, Mathieu S and Adam D: The
apoptosis inhibitory domain of FE65-like protein 1 regulates both
apoptotic and caspase-independent programmed cell death mediated by
tumor necrosis factor. Biochem Biophys Res Commun. 335:575–583.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cullis J, Meiri D, Sandi MJ, Radulovich N,
Kent OA, Medrano M, Mokady D, Normand J, Larose J, Marcotte R, et
al: The RhoGEF GEF-H1 is required for oncogenic RAS signaling via
KSR-1. Cancer Cell. 25:181–195. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liao YC, Ruan JW, Lua I, Li MH, Chen WL,
Wang JR, Kao RH and Chen JH: Overexpressed hPTTG1 promotes breast
cancer cell invasion and metastasis by regulating GEF-H1/RhoA
signalling. Oncogene. 31:3086–3097. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Engels EA, Wu X, Gu J, Dong Q, Liu J and
Spitz MR: Systematic evaluation of genetic variants in the
inflammation pathway and risk of lung cancer. Cancer Res.
67:6520–6527. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu SC, Tsang NM, Chiang WC, Chang KP,
Hsueh C, Liang Y, Juang JL, Chow KP and Chang YS: Leukemia
inhibitory factor promotes nasopharyngeal carcinoma progression and
radioresistance. J Clin Invest. 123:5269–5283. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Momand J, Zambetti GP, Olson DC, George D
and Levine AJ: The mdm-2 oncogene product forms a complex with the
p53 protein and inhibits p53-mediated transactivation. Cell.
69:1237–1245. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chew A, Salama P, Robbshaw A, Klopcic B,
Zeps N, Platell C and Lawrance IC: SPARC, FOXP3, CD8 and CD45
correlation with disease recurrence and long-term disease-free
survival in colorectal cancer. PLoS One. 6:e220472011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li Z, Dong Z, Myer D, Yip-Schneider M, Liu
J, Cui P, Schmidt CM and Zhang JT: Role of 14-3-3σ in poor
prognosis and in radiation and drug resistance of human pancreatic
cancers. BMC Cancer. 10:5982010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shiba-Ishii A and Noguchi M: Aberrant
stratifin overexpression is regulated by tumor-associated CpG
demethylation in lung adenocarcinoma. Am J Pathol. 180:1653–1662.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Carmeliet P: VEGF as a key mediator of
angiogenesis in cancer. Oncology. 69 Suppl 3:S4–S10. 2005.
View Article : Google Scholar
|
|
27
|
Chen CH, Lai JM, Chou TY, Chen CY, Su LJ,
Lee YC, Cheng TS, Hong YR, Chou CK, Whang-Peng J, et al: VEGFA
upregulates FLJ10540 and modulates migration and invasion of lung
cancer via PI3K/AKT pathway. PLoS One. 4:e50522009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Domínguez-Monzón G, Benítez JA, Vergara P,
Lorenzana R and Segovia J: Gas1 inhibits cell proliferation and
induces apoptosis of human primary gliomas in the absence of Shh.
Int J Dev Neurosci. 27:305–313. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhu J and Chen X: MCG10, a novel p53
target gene that encodes a KH domain RNA-binding protein, is
capable of inducing apoptosis and cell cycle arrest in G(2)-M. Mol.
Cell Biol. 20:5602–5618. 2000.
|
|
30
|
Carswell EA, Old LJ, Kassel RL, Green S,
Fiore N and Williamson B: An endotoxin-induced serum factor that
causes necrosis of tumors. Proc Natl Acad Sci USA. 72:pp.
3666–3670. 1975; View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Terai H, Soejima K, Yasuda H, Sato T,
Naoki K, Ikemura S, Arai D, Ohgino K, Ishioka K, Hamamoto J, et al:
Long-term exposure to gefitinib induces acquired resistance through
DNA methylation changes in the EGFR-mutant PC9 lung cancer cell
line. Int J Oncol. 46:430–436. 2015.PubMed/NCBI
|
